Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is making significant strides in precision oncology with its lead candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed for biomarker-selected cancers. The company is advancing the program toward first-in-human studies by establishing the necessary manufacturing and scientific groundwork, including polymer process development and analytical characterization with Nanosoft Polymers, as well as metabolism studies through Nucro-Technics as part of its IND-enabling program.
These efforts are critical for scalable manufacturing and for characterizing ONC010's metabolic profile, which will generate essential data for future pharmacokinetic, toxicology, and regulatory activities. By combining targeted PNKP inhibition with nanoparticle drug delivery and AI-driven discovery capabilities, Onco-Innovations is positioning its development platform to pursue therapies for cancers that may be particularly susceptible to DNA damage response approaches. This is especially relevant as precision medicine continues to expand, offering more personalized treatment options based on genetic and molecular markers.
The significance of these developments lies in the potential of ONC010 to address cancers with specific biomarkers that make them vulnerable to DNA damage response inhibitors. PNKP (polynucleotide kinase 3'-phosphatase) plays a crucial role in DNA repair, and its inhibition can sensitize cancer cells to DNA-damaging agents. By encapsulating the inhibitor in nanoparticles, Onco-Innovations aims to improve drug delivery and reduce systemic toxicity, a common challenge in cancer therapy.
The company's collaboration with Nanosoft Polymers focuses on polymer process development and analytical characterization, which are essential for ensuring the quality and consistency of the nanoparticle formulation. This work supports the scalability needed for clinical and commercial production. Simultaneously, the metabolism studies with Nucro-Technics will provide insights into how ONC010 is processed in the body, a key component of IND-enabling studies.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with a mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumors. For more information, visit the company's website at https://oncoinnovations.com/.
The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF. The full article can be viewed at https://ibn.fm/vLMBt.
